US Stock MarketDetailed Quotes
CRXWQ CLARUS THERAPEUTICS HLDGS INC C/WTS 11/08/2026 (TO PUR COM)
- 0.000
- 0.0000.00%
15min DelayClose Mar 1 16:00 ET
0Market Cap0.00P/E (TTM)
0.000High0.000Low0Volume0.000Open0.000Pre Close0.00Turnover0.00%Turnover Ratio0.00P/E (Static)0Shares0.00052wk High0.00P/B0Float Cap0.00052wk Low--Dividend TTM0Shs Float0.010Historical High--Div YieldTTM0.00%Amplitude0.000Historical Low--Avg Price1Lot Size
About CLARUS THERAPEUTICS HLDGS INC C/WTS 11/08/2026 (TO PUR COM) Company
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Company Profile
SymbolCRXWQ
Company NameCLARUS THERAPEUTICS HLDGS INC C/WTS 11/08/2026 (TO PUR COM)
CEODr. Robert E. Dudley
MarketPink Market
Employees16
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Company Executives
- Name
- Position
- Salary
- Dr. Robert E. Dudley
- Director, President and Chief Executive Officer
- 2.55M
- Frank Jaeger
- Chief Commercial Officer
- 885.27K
- Steven A. Bourne
- Chief Administrative Officer, Secretary and Treasurer
- --
- Richard D. Peterson
- Chief Financial Officer and Principal Accounting Officer
- 1.11M
- Kimberly M. Murphy
- Chairman of the Board
- 74.79K
- Elizabeth A. Cermak
- Independent Director
- 67.82K
- John Kenneth Amory
- Independent Director
- 63.17K
- Alex Zisson
- Independent Director
- --
- Mark A. Prygocki, Sr
- Independent Director
- 183.13K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg